Safety Outcomes / Cancer

((C-206)) (C-206) Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two years of Experience from the CorEvitas AD Registry

((C-207)) (C-207) Implementing robust machine learning pipelines with real-world data: identifying predictors of immune mediated adverse events among patients with advanced melanoma treated with immune checkpoint inhibitors

((C-208)) (C-208) Examining valproate’s potential anticancer effect among patients with bipolar disorder: a territory-wide active-comparator new user study spanning two decades

((C-209)) (C-209) Antidepressant Use and Colonrectal Cancer Risk: A Systematic Review and Meta-Analysis

((C-210)) (C-210) Association Between 5alpha-Reductase Inhibitors and Incident Cancer in Patients with Benign Prostatic Hyperplasia: Evidence from a Matched Cohort Study

((C-211)) (C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis

((C-212)) (C-212) Immune related liver toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers

((C-213)) (C-213) Immune related kidney toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers

((C-214)) (C-214) Second Primary Malignancy in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anticancer Therapy: A Comparative Study Using a Real-World Database

((C-215)) (C-215) Methodological Approaches to Capture Real-World Adverse Events (AEs) of first-line (1L) Systemic Treatments in Electronic Health Records (EHRs) in a cohort of Patients With Locally Advanced/Metastatic Urothelial Cancer (la/mUC)

((C-216)) (C-216) Diuretics are associated with rates of basal and squamous cell carcinomas of the skin in the U.S. Medicare population with hypertension

((C-217)) (C-217) Incidence of Cataract Among Patients Exposed to FGFR Inhibitors in the Real-World

((C-218)) (C-218) Use of Systemic Glucocorticoids and Risk of Prostate Adenocarcinoma: Evidence From a Danish Population-Based Case-Control Study

((C-219)) (C-219) Quality Evaluation of Previous Studies on Glucocorticoid Use and Risk of Site-Specific Cancers: A Systematic Review

((C-220)) (C-220) Global Feasibility Assessment of Real-World Databases for Long-Term Safety of Vitiligo Treatments

((C-221)) (C-221) Atrial Fibrillation and Bleeding in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) on Ibrutinib vs Acalabrutinib: Role of Age, Frailty, and Anticoagulants

((C-222)) (C-222) Incidence of second primary T-cell non-Hodgkin lymphoma among multiple myeloma patients: evidence from real-world data

((C-223)) (C-223) Chimeric Antigen Receptor Therapy (CAR T) Therapy and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): A Systematic Review and Meta-analysis

((C-224)) (C-224) Impact of Systemic Corticosteroid Use on Survival Outcomes in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study

((C-225)) (C-225) Adverse events of treatment and characteristics of patients with multiple myeloma: a Brazilian historical cohort study

((C-226)) (C-226) Efficacy and Safety of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.